HC Wainwright Issues Positive Estimate for Nuvalent Earnings

Nuvalent, Inc. (NASDAQ:NUVL) – Investment analysts at HC Wainwright lifted their FY2026 earnings estimates for Nuvalent in a report released on Tuesday, June 24th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($3.19) for the year, up from their previous forecast of ($3.24). HC Wainwright currently has a “Buy” rating and a $130.00 price objective on the stock. The consensus estimate for Nuvalent’s current full-year earnings is ($3.86) per share. HC Wainwright also issued estimates for Nuvalent’s Q4 2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.12) EPS, FY2028 earnings at $2.96 EPS and FY2029 earnings at $7.50 EPS.

Several other research firms have also weighed in on NUVL. Wedbush restated an “outperform” rating and set a $115.00 target price on shares of Nuvalent in a report on Tuesday. UBS Group upgraded Nuvalent from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a report on Friday, March 14th. Leerink Partners upped their target price on Nuvalent from $125.00 to $140.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Robert W. Baird lifted their price target on shares of Nuvalent from $105.00 to $112.00 and gave the company an “outperform” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $119.60.

Nuvalent Stock Performance

Shares of NASDAQ NUVL opened at $79.13 on Thursday. The business has a 50 day simple moving average of $74.57 and a 200 day simple moving average of $76.43. Nuvalent has a 52 week low of $55.54 and a 52 week high of $113.51. The stock has a market cap of $5.68 billion, a price-to-earnings ratio of -18.03 and a beta of 1.34.

Nuvalent (NASDAQ:NUVL) last released its earnings results on Thursday, May 8th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.14) by ($0.04). During the same quarter in the prior year, the firm posted ($0.69) earnings per share.

Institutional Trading of Nuvalent

Several large investors have recently added to or reduced their stakes in NUVL. Boxer Capital Management LLC bought a new position in shares of Nuvalent in the fourth quarter valued at approximately $87,689,000. Vestal Point Capital LP acquired a new position in Nuvalent during the 4th quarter worth about $46,968,000. Braidwell LP grew its holdings in Nuvalent by 248.6% during the 1st quarter. Braidwell LP now owns 840,945 shares of the company’s stock worth $59,640,000 after acquiring an additional 599,710 shares during the last quarter. Polar Capital Holdings Plc grew its holdings in Nuvalent by 161.2% during the 4th quarter. Polar Capital Holdings Plc now owns 946,723 shares of the company’s stock worth $74,109,000 after acquiring an additional 584,223 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in Nuvalent in the 1st quarter valued at about $31,969,000. 97.26% of the stock is owned by institutional investors.

Insider Transactions at Nuvalent

In related news, CEO James Richard Porter sold 27,000 shares of Nuvalent stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $68.94, for a total transaction of $1,861,380.00. Following the completion of the transaction, the chief executive officer now directly owns 249,062 shares of the company’s stock, valued at $17,170,334.28. This trade represents a 9.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.20% of the stock is owned by insiders.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.